Adicet Bio, Inc. (ACET) Institutional Ownership

Ownership Summary

Recent 13F filings as of December 2025 show that 48 institutional investors hold a position in Adicet Bio, Inc. (NASDAQ:ACET).

• The collective stake of institutional investors in Adicet Bio moved to 117.5% in December 2025, a shift up from the 55.7% reported for September 2025.
• On a quarter-over-quarter basis, institutional holdings shifted by 11071.14%, with a year-over-year a decrease of 26.15% in the count of filers.
• A review of institutional activity for Adicet Bio shows 47 of 48 filers increasing their positions, while 1 reduced their stake, and 0 remained unchanged.
• The aggregate institutional position in Adicet Bio now stands at 6.76Mn shares as of December 2025, after investors increased their holdings (up by 6.70Mn shares quarter on quarter which is up 3.16Mn shares year over year).
• ORBIMED ADVISORS LLC continues to be the largest institutional holder of Adicet Bio as of December 31, 2025, with a position of 1.03Mn shares, representing 17.88% of the company's outstanding stock.
• Among the most significant buyers of Adicet Bio during December 2025 were ORBIMED ADVISORS LLC (1.03Mn), RA CAPITAL MANAGEMENT, L.P. (948.25K), FRANKLIN RESOURCES INC (626.57K), Woodline Partners LP (625.00K), VANGUARD GROUP INC (291.28K).
• Leading sellers of Adicet Bio stock in December 2025 included REGENERON PHARMACEUTICALS, INC. (0).
• The top 10 institutional holders of Adicet Bio for the quarter ending December 2025 included ORBIMED ADVISORS LLC (1.03Mn), RA CAPITAL MANAGEMENT, L.P. (948.25K), FRANKLIN RESOURCES INC (626.57K), Woodline Partners LP (625.00K), VANGUARD GROUP INC (291.28K), ADAGE CAPITAL PARTNERS GP, L.L.C. (274.38K), Prosight Management, LP (250.24K), RENAISSANCE TECHNOLOGIES LLC (242.94K), GOLDMAN SACHS GROUP INC (234.51K), Stonepine Capital Management, LLC (220.01K).